1. |
Roberts JM, Bell MJ. If we know so much about preeclampsia, why haven't we cured the disease?. J Reprod Immunol, 2013, 99(1/2): 1-9.
|
2. |
Steegers Eric AP, Von Dadelszen P, Duvekot JJ, et al. Pre-eclampsia. Lancet, 2010, 376(9741): 631-644.
|
3. |
Nassiri F, Cusimano MD, Scheithauer BW, et al. Endoglin (CD105): a review of its role in angiogenesis and tumor diagnosis, progression and therapy. Anticancer Res, 2011, 31(6): 2283-2290.
|
4. |
Verdonk K, Visser W, Van Den Meiracker AH, et al. The renin-angiotensin-aldosterone system in pre-eclampsia: the delicate balance between good and bad. Clin Sci (Lond), 2014, 126(8): 537-544.
|
5. |
Liu X, Deng Q, Luo X, et al. Oxidative stress-induced Gadd45alpha inhibits trophoblast invasion and increases sFlt1/sEng secretions via p38 MAPK involving in the pathology of pre-eclampsia [J]. J Matern Fetal Neonatal Med, 2016, 29(23):3776-3785.
|
6. |
中华医学会妇产科分会妊娠期高血压疾病学组. 妊娠期高血压疾病诊疗指南(2012). 中华妇产科杂志, 2012, 47(6): 476-480.
|
7. |
Lim JH, Kim SY, Park SY, et al. Soluble endoglin and transforming growth factor-beta1 in women who subsequently developed preeclampsia. Prenat Diagn, 2009, 29(5): 471-476.
|
8. |
Mutter WP, Karumanchi SA. Molecular mechanisms of preeclampsia. Microvasc Res, 2008, 75(1): 1-8.
|
9. |
Fang M, He Y, Li H, et al. Alterations of serum and placental endoglin in pre-eclampsia. J Int Med Res, 2010, 38(1): 43-51.
|
10. |
Paasche Roland MC, Lorentzen B, Godang K, et al. Uteroplacental arterio-venous difference in soluble VEGFR-1 (sFlt-1), but not in soluble endoglin concentrations in preeclampsia. Placenta, 2012, 33(3): 224-226.
|
11. |
Makris A, Thornton C, Thompson J, et al. Uteroplacental ischemia results in proteinuric hypertension and elevated sFLT-1. Kidney Int, 2007, 71(10): 977-984.
|
12. |
Rizos D, Eleftheriades M, Karampas G, et al. Placental growth factor and soluble fms-like tyrosine kinase-1 are useful markers for the prediction of preeclampsia but not for small for gestational age neonates: a longitudinal study. Eur J Obstet Gynecol Reprod Biol, 2013, 171(2): 225-230.
|
13. |
Venkatesha S, Toporsian M, Lam C, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med, 2006, 12(6): 642-649.
|
14. |
Stepan H, Geipel A, Schwarz F, et al. Circulatory soluble endoglin and its predictive value for preeclampsia in second-trimester pregnancies with abnormal uterine perfusion. Am J Obstet Gynecol, 2008, 198(2): 175.e1-175.e6.
|
15. |
Romero R, Nien JK, Espinoza J, et al. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med, 2008, 21(1): 9-23.
|
16. |
Fan X, Rai A, Kambham N, et al. Endometrial VEGF induces placental sFLT1 and leads to pregnancy complications. J Clin Invest, 2014, 124(11): 4941-4952.
|